Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody.
Ziduo Li; Edward Abadir; Kenneth Lee; Candice Clarke; Christian E Bryant; Wendy Cooper; Geoffrey Pietersz; James Favaloro; Pablo A Silveira; Derek Nj Hart; Xinsheng Ju; Georgina J Clark
Effective antibody-drug conjugates (ADCs) provide potent targeted cancer therapies. CD83 is expressed on activated immune cells including B cells and is a therapeutic target for Hodgkin lymphoma. Our objective was to determine CD83 expression on non-Hodgkin lymphoma (NHL) and its therapeutic potential to treat mantle cell lymphoma (MCL) which is currently an incurable NHL.We analysed CD83 expression on MCL cell lines and the lymph node/bone marrow biopsies of MCL patients. We tested the killing effect of CD83 ADC and in an xenograft MCL mouse model.in vitroCD83 is expressed on MCL, and its upregulation is correlated with the nuclear factor κB (NF-κB) activation. CD83 ADC kills MCL and . Doxorubicin and cyclophosphamide (CP), which are included in the current treatment regimen for MCL, enhance the NF-κB activity and increase CD83 expression on MCL cell lines. The combination of CD83 ADC with doxorubicin and CP has synergistic killing effect of MCL.in vitroThis study provides evidence that a novel immunotherapeutic agent CD83 ADC, in combination with chemotherapy, has the potential to enhance the efficacy of current treatments for MCL.
|Journal||CLINICAL & TRANSLATIONAL IMMUNOLOGY|
|Published||01 Jan 2020|